Nucleai

📍 Chicago, United States🗓 Founded 2018👥 117 employees💰 Last funded Jan 2024
Nucleai Brings AI-powered spatial biology technology to the forefront of precision medicine to improve drug development, clinical treatment decisions, and patient outcomes. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects. Nucleai’s Atom: The leading Spatial Biology Platform for Precision Medicine.
5
Total investors
4
Early stage
0
Mid stage
1
Late stage
2018
Founded
Investor geography2 countries
Israel
4
United States
1
Investor activity2018–2024 · investors recorded per year
201822020220241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Nucleai?
Nucleai has 5 investors on record on gritt.io, including 4 early-stage backers and 1 late-stage investors.
When did Nucleai last raise funding?
The most recent investment in Nucleai recorded on gritt.io was in January 2024.
When was Nucleai founded?
Nucleai was founded in 2018.
What industry is Nucleai in?
Nucleai operates in Software Development. Find similar Software Development investors on gritt.io.
Where is Nucleai based?
Nucleai is headquartered in Chicago, United States.